Salute e Benessere

AIMA Technology Group to Unveil Seven New Electric Mobility Products at CES 2025…

AIMA Technology Group's global expansion is accelerating, having already covered over 50 countries, with a cumulative sales volume exceeding 80 million units by 2023. The showcase at CES 2025 will further strengthen AIMA Technology Group's leadership in the global electric mobility market. AIMA Technology Group's global expansion is accelerating, having already covered over 50 countries, with a cumulative sales volume exceeding 80 million units by 2023. The showcase at CES 2025 will further...
PR Newswire
24/12/2024

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

rdAnnual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time).To access a live webcast of the presentation, visit Teva's Investor Relations website athttps://ir.tevapharm.com/Events-and-Presentations.An archived version of the webcast will be available within 24 hours after the end of the live discussion. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global...
Nasdaq GlobeNewswire
23/12/2024

Scientists report studies showing a novel drug repairs myelin and restores…

etal; was published in the December 21, 2024 edition ofActa Neuropathologica Communications.IRX4204 selectively activates the retinoid X receptor (RXR). Given compelling links between RXR activation and increased myelin repair, the collaborating scientists employed IRX4204 to investigate the impact of RXR agonism on functional recovery in mice subjected to experimental autoimmune encephalomyelitis (EAE). EAE is a commonly used model of neuroinflammation in human MS. Machine learning...
Nasdaq GlobeNewswire
23/12/2024

Safe Life Enters French Market with Strategic Acquisition of D-Sécurité Groupe

"We are thrilled to welcome D-Sécurité to the Safe Life family," says Jimmy Eriksson, CEO of Safe Life. "This acquisition is a key step in our mission to bring life-saving solutions to as many people as possible. Not only does D-Sécurité bring a wealth of expertise and an impressive team, but their established presence in France gives us a strong foundation to grow in this important market." "We are thrilled to welcome D-Sécurité to the Safe Life family," saysJimmy…
PR Newswire
23/12/2024

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

The article continued: Additionally, the oncology sector has attracted significant investment, with companies like Ottimo Pharma raising $140 million to develop more effective cancer treatments with fewer side effects—highlighting the industry's commitment to addressing the global cancer burden. The article continued: Additionally, the oncology sector has attracted significant investment, with companies likeOttimo Pharma raising$140 million to develop more effective cancer treatments...
PR Newswire
23/12/2024

Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of…

About Stapokibart About Stapokibart Stapokibart (trade name: Kangyueda, R&D codename: CM310) is a high-efficient, humanized antibody targeting the interleukin-4 receptor alpha subunit (IL-4Rα), and is the first domestically manufactured IL-4Rα antibody drug granted marketing approval by the NMPA. By targeting IL-4Rα, Stapokibart can block both interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling. IL-4 and IL-13 are two key cytokines that trigger type II inflammation. Stapokibart...
PR Newswire
23/12/2024

XBiotech Pauses Rheumatology program

Findings from recently completed Rheumatoid Arthritis Study raise questions About 230 subjects with moderate to severe rheumatoid arthritis were enrolled into the Phase II arthritis study, which examined the Company's candidate drug, Natrunix, in combination with methotrexate (MTX). The study's primary endpoint was the American College of Rheumatology (ACR) 20 response rate after 12 weeks of treatment. Various other rheumatological assessments were also performed, including NRS-pain scores,...
Nasdaq GlobeNewswire
23/12/2024

RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding…

LUMINA is an Advanced Minimal Residual Disease Detection Platform for Lung Cancer Harnessing the Power of Multi-omics Biomarkers and AI LOS ANGELES and AMSTERDAM, Dec.23, 2024(GLOBE NEWSWIRE) --Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced its subsidiaryRenovaroCube (the 'Cube'), a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, together with its consortium...
Nasdaq GlobeNewswire
23/12/2024

H.I.G. Realty Announces Strategic Partnership with Queen Mary BioEnterprises…

Additionally, the development of a state-of-the-art incubator space and its shared services will create a venture-building environment and ecosystem, critical in attracting startup companies and spinouts. QMB's extensive experience operating incubator spaces will also help deliver long-term, high-quality jobs to the Whitechapel area, foster career pathways, and promote education in the life sciences and STEM sectors. Additionally, the development of a state-of-the-art incubator space and its...
PR Newswire
23/12/2024

OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI® Enabling…

Under the terms of the Marketing Agreement, OBI grants GlyTech rights to market and promote OBI's GlycOBI® ADC enabling technologies, powered by EndoSymeOBI®, to potential pharma and biotech partners in Japan. GlyTech will also be a key supplier of glycans in Japan. Under the terms of the Material Transfer Agreement, OBI will transfer some of its cutting-edge materials to GlyTech for research in advancing the efficient production of glycans for ADCs.Heidi Wang, Ph.D., OBI Pharma's Chief...
Nasdaq GlobeNewswire
23/12/2024

THE STATE OF GLOBAL OPTIMISM REVEALED BY LG IN NEW SURVEY

The survey, conducted across 16 markets, provides extensive data on global optimism, its drivers and the demographics that feel the most optimistic and happy. The global average optimism score is 7.49/10. France, the UK and Australia were revealed to be among the least optimistic countries, scoring 14.5 percent below the average. Conversely, Saudi Arabia (12 percent above), India (10.8 percent above) and the UAE (8.1 percent above) were the most optimistic. Consumers were most optimistic about…
PR Newswire
23/12/2024

Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024

Addition is part of the annual reconstitution of the Nasdaq Biotech Index (NBI)Inclusion criteria include minimum market capitalization and daily trading volumesAlvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its stock will be added to the Nasdaq Biotechnology Index (NASDAQ: NBI). The addition comes as a part of the annual reconstitution of the index. Alvotech's...
Nasdaq GlobeNewswire
23/12/2024

Implantica to be included in Nasdaq's First North 25 index

Implantica founder and CEO, Peter Forsell, says, "It is an honor to be selected for inclusion in the FN 25 index and validates the high interest Implantica has received from investors, especially since we have submitted the first two of three modules of RefluxStop's PMA application to FDA, for approval to sell in the U.S. Implantica founder and CEO,Peter Forsell, says, "It is an honor to be selected for inclusion in the FN 25 index and validates the high interest Implantica has…
PR Newswire
23/12/2024

Basilea is awarded additional CARB-X funding to develop new drug candidate from…

Additional funding awarded following successful drug candidate nominationUSD 7.3 million to support progression of antibiotic BAL2420 (LptA inhibitor) towards first-in-human clinical studies Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland, December 23, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it...
Nasdaq GlobeNewswire
23/12/2024

Press Release: Sanofi initiates phase 3 program for PCV21 and expands…

Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccinesPneumococcal disease remains a major global health challenge despite the availability of current vaccines This 21-valent pneumococcal conjugate vaccine (PCV21) is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter phase 3 in infants & toddlers Paris, December 23, 2024. Sanofi and SK bioscience have...
Nasdaq GlobeNewswire
23/12/2024

Press release: Sequana Medical Announces US FDA Approval of alfapump® for the…

Sequana Medical Announces US FDA Approval of alfapump ®for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis alfapump ®is the first US approved active implantable medical device (Class III) for the treatment of recurrent or refractory ascites due to liver cirrhosisPMA Approval and FDA Breakthrough Device DesignationUS market opportunity estimated at over $2 billion in 2025, growing at 9% 1due to MASH/NASH 2and alcoholic liver diseaseUS...
Nasdaq GlobeNewswire
23/12/2024

Fagron updates on FDA communication regarding the June 2024 inspection at…

Regulated information – inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 23 Dec 2024 – 7AM CET Fagron updates on FDA communication regarding the June 2024 inspection at WichitaFollowing the FDA's routine inspection at Fagron's Wichita facility conducted in June 2024, the Company received a warning letter from the FDA (Warning Letter) on December 19, 2024. The Warning Letter requires Fagron to enhance processes for investigating discrepancies, and validations of...
Nasdaq GlobeNewswire
23/12/2024

Aptamer developed by HKBU for treating rare bone disease 'X-linked…

Professor Zhang Ge, Associate Dean (Research) of Chinese Medicine and Director of the Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases at HKBU, and Professor Zhang Zhenlin, Director of Osteoporosis and Bone Diseases of the Shanghai Sixth People's Hospital, along with Aptacure Therapeutics Ltd., have developed a long-acting sclerostin-loop3 oligonucleotide aptamer for the treatment of XLH. This aptamer has been granted Orphan Drug Designation and Pediatric…
PR Newswire
23/12/2024

ZINZINO AB (PUBL.): ENTERS INTO AGREEMENT TO PROVIDE DIP FINANCING TO ZURVITA…

Zurvita is a direct selling health company with operations in the United States, Canada and Mexico. The brand portfolio offers a range of innovative health and wellness products. The business has total annual sales of approximately USD 30 million with good gross margins. A potential transaction with Zinzino is expected to add growth through the synergies arising from the joint networks, combined with Zinzino's test-based product concept. The profitability of the Company will thus be able to…
PR Newswire
22/12/2024

Publication relating to transparency notifications

REGULATED INFORMATIONPublication relating to transparency notificationsMont-Saint-Guibert(Belgium), December 20, 2024 , 10:30 pm CET / 4:30 pm ET –In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.BlackRock, Inc.On December 19, 2024, Nyxoah received a transparency notification from...
Nasdaq GlobeNewswire
20/12/2024

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024…

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2024 financial results, as well as on its financial guidance for 2025, on Wednesday, January 29, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.In order to participate, please register in advancehere to obtain a local or toll-free phone number and your...
Nasdaq GlobeNewswire
20/12/2024

Renovaro Regains Compliance with NASDAQ Listing Requirement

Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced that it has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule, 5550(a)(2). The Company's security will continue to be listed and traded on The Nasdaq Stock Market and this matter is now closed...
Nasdaq GlobeNewswire
20/12/2024

Press Release: Sequana Medical announces results of Extraordinary General…

Sequana Medical announces results of Extraordinary General Meeting of Shareholders and update on Convertible FinancingGhent, Belgium – 20 December 2024– Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that the proposed resolution submitted to the extraordinary general shareholders' meeting was approved at the meeting held today at…
Nasdaq GlobeNewswire
20/12/2024

Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

The article continued: Additionally, the American Cancer Society has spotlighted an alarming rise in cancer incidence and mortality among younger age groups. Analysts at Exactitude Consultancy anticipate that the global Cancer Immunotherapy Market will expand at a robust 12.84% CAGR, reaching $258.22 billion by 2031—a clear indicator of oncology's rapid growth and critical importance. The article continued: Additionally, theAmerican Cancer Societyhas spotlighted an alarming rise incancer...
PR Newswire
20/12/2024
Altri  Comunicati